Servier`s Biologic Asparlas (Calaspargase Pegol-mknl) Receives Approval in the U.S.
Sigma's Biologic Oncaspar (Pegaspargase) Receives Approval in the U.S.
BOSTON, Dec. 12, 2022 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced findings from a retrospective study observing higher overall survival (OS) in adolescent and young adult (AYA) newly-diagnosed acute lymphoblastic leukemia (ALL) patients treated with asparaginase containing pediatric-inspired regimens (PIR) versus non-pediatric-inspired regimens. Detailed results from the new real-world analysis were presented today in an oral session at the 64th Annual Meeting of the American Society of Hematology (ASH).
Servier Pharma`s Biologic Asparlas (Calaspargase Pegol- mknl) Receives Approval in the U.S.
DUBLIN, Dec. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity or silent inactivation to an E. coli-derived asparaginase. The study was developed and conducted in close collaboration with the Children's Oncology Group (COG). These initial results will be presented for the first time today at the 63rd American Society of Hematology (ASH) Annual Meeting.
Servier's Asparlas (calaspargase pegol) Receives Supplemental Approval In US
Sigma Tau`s Oncospar (Pegaspargase) Receives Supplemental Approval in US
ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that the full results from its Phase 2b trial evaluating eryaspase in metastatic pancreatic cancer are now published online in the European Journal of Cancer.
U.S. sanctions on Iran threaten access by some Iranians to medicines that treat diseases such as cancer and epilepsy, despite exemptions in the measures for imports of humanitarian goods, a report said on Tuesday.